摘要胰腺癌是目前已知的恶性程度最高的消化道肿瘤之一，具有起病隐匿、进展迅速、病程极短、病死率高等临床特点，中位生存期约6个月，5年生存率不到5％［1］。迄今，吉西他滨仍然是胰腺癌一线化疗的金标准药物，但疗效远不能令人满意，我科2010年2月至2012年1月采用吉西他滨联合替吉奥（G S ）方案化疗同步调强放疗治疗42例胰腺癌效果显著，现报告如下。
5Nakai Y, Isayama H, Sasak T, et al. Impact of S-1 on the surviv al of patients with advanced pancreatic cancer[J] Pancreas, 2010, 39(7) : 989-993.
6Okusaka T, Ito Y, Furuse J, et al. Current status of chemo- radiotherapy for locally advanced pancreatic cancer in Japan [J]. Int J Clin Oncol, 2008 ,13 :127- 131.
7Takagi M, Sakata K, Someya M, et al. Gimeraeil sensitizes ceils to radiation via inhibition of homologous recombination[J]. Radiother Oncol , 2010,96(2):259-266.
3Freelove R,Walling AD.Pancreatic cancer:diagnosis and management[J].Am Fam Physician,2006,73 (3):485-492.
4Michaud D S.Epidemiology of pancreatic cancer[J].Minerva Chir,2004,59(2):99-111.
5StornioloAM,EnasNH,Brown CA,et al.An investigation news drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma[J].Cancer,1999,85(6):1261-1268.
6Burrisha,Moorem J,Anadersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].Clin Onco,1997,15(6):2403-2413.
7DiCostanzo F,Carlini P,Doni L,et al.Gemcitabine with or without continuous imfusion 5-Fu in advanced pancreatic cancer:a randomised phaseⅡtrial of the Italian oncology group for clinical research (GOIRC)[J].Br Cancer,2005,93 (2):185-189.
8OettleH,RichardsD,Ramanathan PK,et al.AphaseⅢtrial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J].Ann Onco,2005,16(10):1639-1645.
9Rocha Lima CM,GreenMR,Rotche R,et al.Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced ormetastatic pancreatic cancer despite increased tumor response rate[J].Clin Oncol,2004,22(18):3776-3783.
10Louvet C,Labianca R,Hammel P,et al.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:results of a GERCOR and GISCAD phaseⅢtrial[J].Clin Onco,2005,23(15):3509-3516.
